Literature DB >> 32880071

Parkinson's disease laterality: a 11C-PE2I PET imaging study.

Andreas-Antonios Roussakis1, Zhou Zeng1,2, Nicholas P Lao-Kaim1, Antonio Martin-Bastida1,3, Paola Piccini4.   

Abstract

Asymmetry of striatal dopaminergic deficits and motor symptoms is a typical characteristic of idiopathic Parkinson's disease (PD). This study aims to characterise the trend of asymmetry in moderate-stage PD. We performed a 19-month longitudinal study in 27 patients with PET-CT imaging and appropriate clinical assessments. 11C-PE2I non-displaceable binding potential (BPND) was calculated bilaterally for the striatum at baseline and follow-up to estimate the in vivo density of striatal dopamine transporters (DAT). Changes in striatal 11C-PE2I BPND over time were more prominent in the ipsilateral as compared to contralateral side. Changes in MDS-UPDRS-III (motor component of the Movement Disorders Society Unified PD Rating Scale) were not different between the clinically most and least affected body sides. Our data support that the asymmetry in striatal dopaminergic degeneration becomes less prominent in moderate-stage PD. In contrast, during the above period, the asymmetry of motor symptoms was maintained between the clinically most and least affected body sides.

Entities:  

Keywords:  Asymmetry; Dopamine transporter; Parkinson’s disease; Positron emission tomography; Striatum

Mesh:

Substances:

Year:  2020        PMID: 32880071      PMCID: PMC7880931          DOI: 10.1007/s00415-020-10204-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  34 in total

1.  11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study.

Authors:  Weihua Li; Nick P Lao-Kaim; Andreas A Roussakis; Antonio Martín-Bastida; Natalie Valle-Guzman; Gesine Paul; Clare Loane; Håkan Widner; Marios Politis; Tom Foltynie; Roger A Barker; Paola Piccini
Journal:  Mov Disord       Date:  2017-10-30       Impact factor: 10.338

2.  Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I.

Authors:  H Hall; C Halldin; D Guilloteau; S Chalon; P Emond; J Besnard; L Farde; G Sedvall
Journal:  Neuroimage       Date:  1999-01       Impact factor: 6.556

3.  Motor asymmetry over time in Parkinson's disease.

Authors:  Cameron Miller-Patterson; Richard Buesa; Nicole McLaughlin; Richard Jones; Umer Akbar; Joseph H Friedman
Journal:  J Neurol Sci       Date:  2018-08-03       Impact factor: 3.181

4.  Parkinson disease: handedness predicts asymmetry.

Authors:  R J Uitti; Y Baba; N R Whaley; Z K Wszolek; J D Putzke
Journal:  Neurology       Date:  2005-06-14       Impact factor: 9.910

5.  In vivo dopamine transporter imaging in a unilateral 6-hydroxydopamine rat model of Parkinson disease using 11C-methylphenidate PET.

Authors:  Vesna Sossi; Katherine Dinelle; Salma Jivan; Kristina Fischer; James E Holden; Doris Doudet
Journal:  J Nucl Med       Date:  2012-04-09       Impact factor: 10.057

Review 6.  Imaging dopamine transporters in Parkinson's disease.

Authors:  David J Brooks
Journal:  Biomark Med       Date:  2010-10       Impact factor: 2.851

7.  Progression from unilateral to bilateral parkinsonism in early Parkinson disease: implication of mesocortical dopamine dysfunction by PET.

Authors:  Shunsuke Yagi; Etsuji Yoshikawa; Masami Futatsubashi; Masamichi Yokokura; Yujiro Yoshihara; Tatsuo Torizuka; Yasuomi Ouchi
Journal:  J Nucl Med       Date:  2010-07-21       Impact factor: 10.057

8.  Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.

Authors:  Robert A Hauser; Olivier Rascol; Amos D Korczyn; A Jon Stoessl; Ray L Watts; Werner Poewe; Peter P De Deyn; Anthony E Lang
Journal:  Mov Disord       Date:  2007-12       Impact factor: 10.338

9.  Clinical evolution of Parkinson's disease and prognostic factors affecting motor progression: 9-year follow-up study.

Authors:  G Reinoso; J C Allen; W-L Au; S-H Seah; K-Y Tay; L C S Tan
Journal:  Eur J Neurol       Date:  2014-06-02       Impact factor: 6.089

10.  Synucleins antagonize endoplasmic reticulum function to modulate dopamine transporter trafficking.

Authors:  Adam W Oaks; Nicholas Marsh-Armstrong; Jessica M Jones; Joel J Credle; Anita Sidhu
Journal:  PLoS One       Date:  2013-08-13       Impact factor: 3.240

View more
  1 in total

1.  Adenosine A2A receptor availability in patients with early- and moderate-stage Parkinson's disease.

Authors:  Imran Waggan; Eero Rissanen; Jouni Tuisku; Juho Joutsa; Semi Helin; Riitta Parkkola; Juha O Rinne; Laura Airas
Journal:  J Neurol       Date:  2022-09-02       Impact factor: 6.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.